AR081471A1 - Profarmacos de peptido de la superfamilia de glucagon basado en amida - Google Patents
Profarmacos de peptido de la superfamilia de glucagon basado en amidaInfo
- Publication number
- AR081471A1 AR081471A1 ARP110102184A ARP110102184A AR081471A1 AR 081471 A1 AR081471 A1 AR 081471A1 AR P110102184 A ARP110102184 A AR P110102184A AR P110102184 A ARP110102184 A AR P110102184A AR 081471 A1 AR081471 A1 AR 081471A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- glucagon superfamily
- peptide
- group
- nhr6
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 5
- 108060003199 Glucagon Proteins 0.000 title abstract 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 5
- 229960004666 glucagon Drugs 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 230000004962 physiological condition Effects 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000002144 chemical decomposition reaction Methods 0.000 abstract 1
- 238000006911 enzymatic reaction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35818810P | 2010-06-24 | 2010-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081471A1 true AR081471A1 (es) | 2012-09-05 |
Family
ID=45372025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102184A AR081471A1 (es) | 2010-06-24 | 2011-06-23 | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8778872B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2588126A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013540102A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130102470A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103179979A (cg-RX-API-DMAC7.html) |
| AR (1) | AR081471A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2796894A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012014576A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2580317C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201209062A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011163012A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| MX2010004297A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Antagonistas de glucagon. |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| WO2010080609A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| RU2550696C2 (ru) | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| IN2012DN06437A (cg-RX-API-DMAC7.html) * | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
| CA2803164C (en) | 2010-06-24 | 2018-08-21 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| MX355543B (es) | 2010-08-13 | 2018-04-20 | Aileron Therapeutics Inc Star | Macrociclos peptidomiméticos. |
| EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| PE20140765A1 (es) | 2011-06-10 | 2014-06-14 | Hanmi Science Co Ltd | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos |
| UA125895C2 (uk) | 2011-06-17 | 2022-07-06 | Ханмі Сайенс Ко., Лтд. | КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ |
| EA031230B1 (ru) | 2011-06-22 | 2018-12-28 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты глюкагонового рецептора/glp-1-рецептора |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
| CN103957927B (zh) | 2011-11-17 | 2016-11-09 | 印第安纳大学研究及科技有限公司 | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 |
| WO2013096386A1 (en) | 2011-12-20 | 2013-06-27 | Indiana University Research And Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
| JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| EP2820038B1 (en) * | 2012-03-01 | 2020-06-17 | Novo Nordisk A/S | Glp-1 prodrugs |
| CN104271742B (zh) * | 2012-03-04 | 2018-06-05 | 株式会社博纳克 | 微小rna抑制剂 |
| AU2013277372B2 (en) * | 2012-06-21 | 2018-03-29 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting GIP receptor activity |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| JP6387008B2 (ja) | 2012-09-26 | 2018-09-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリンアナローグダイマー |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014073842A1 (en) | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| RS57531B1 (sr) | 2012-12-21 | 2018-10-31 | Sanofi Sa | Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| CN105324125A (zh) * | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| WO2015006141A1 (en) * | 2013-07-08 | 2015-01-15 | The Regents Of The University Of California | Carboxymethylcellulose-peptide conjugates and methods for using the same |
| WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| CA2932477C (en) | 2013-12-06 | 2023-10-10 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| EP3197912B1 (en) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Lipidated amide-based insulin prodrugs |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| EP3825324A1 (en) | 2014-10-24 | 2021-05-26 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2018009778A1 (en) * | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes |
| ES2989204T3 (es) | 2017-06-16 | 2024-11-25 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| CN116143939A (zh) * | 2017-11-24 | 2023-05-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
| EP3852786A4 (en) * | 2018-09-19 | 2022-09-28 | Georgia Tech Research Corporation | SELF-TITRATEING BACTERIAL PROTEASE-ACTIVATED PRODRUG |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| KR20230022949A (ko) * | 2020-06-03 | 2023-02-16 | 쾨벤하운스 유니버시테트 | Glp1r 작용제 nmdar 길항제 접합체 |
| IL299701A (en) | 2020-07-22 | 2023-03-01 | Novo Nordisk As | GLP-1 and GIP receptor co-agonists suitable for oral administration |
| EP4240420A1 (en) | 2020-11-06 | 2023-09-13 | Novo Nordisk A/S | Glp-1 prodrugs and uses hereof |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
| CN114636773B (zh) * | 2022-05-23 | 2022-08-23 | 广东国标医药科技有限公司 | 一种药用辅料中聚乙二醇单甲醚2000的含量测定方法 |
| TW202421645A (zh) | 2022-11-25 | 2024-06-01 | 丹麥商諾佛 儂迪克股份有限公司 | 如ｇｌｐ—１之肽治療劑的口服投與 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US171920A (en) | 1876-01-11 | Improvement in hat and coat hooks | ||
| US3740385A (en) | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| ATE123780T1 (de) | 1989-02-17 | 1995-06-15 | Chiron Mimotopes Pty Ltd | Verfahren zur verwendung und herstellung von peptiden. |
| ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| CA2208215A1 (en) | 1995-10-12 | 1997-04-17 | Supergen, Inc. | Liposome formulations of 5.beta. steroids |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| AU2263197A (en) | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
| AU724326B2 (en) | 1996-09-09 | 2000-09-14 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| BR9916027A (pt) * | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| AU3441400A (en) | 1999-03-29 | 2000-10-16 | Uutech Limited | Peptide |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AUPQ661800A0 (en) | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| AU2001257278A1 (en) | 2000-04-27 | 2001-11-07 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| WO2001096368A2 (en) | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| ES2275685T3 (es) | 2000-06-16 | 2007-06-16 | Eli Lilly And Company | Analogos del peptido similar a glucagon 1. |
| BR0113178A (pt) | 2000-08-02 | 2004-04-06 | Theratechnologies Inc | Peptìdeos biológicos modificados com potência aumentada |
| GB2382346B (en) | 2000-08-04 | 2004-08-11 | Dmi Biosciences Inc | Method of synthesizing diketopiperazines |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1324779B1 (en) | 2000-09-29 | 2011-07-20 | Schering Corporation | Pegylated interleukin-10 |
| AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7083970B2 (en) | 2001-04-19 | 2006-08-01 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| EP2022505B1 (en) | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| WO2003014318A2 (en) | 2001-08-08 | 2003-02-20 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| AU2002322403A1 (en) | 2001-08-23 | 2003-03-10 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| US7238663B2 (en) | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| MXPA04003553A (es) | 2001-10-18 | 2004-07-22 | Bristol Myers Squibb Co | Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas. |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| EP1448222A4 (en) | 2001-10-19 | 2006-05-17 | Lilly Co Eli | BIPHASIC MIXTURES OF GLP-1 AND INSULIN |
| CZ2004710A3 (cs) | 2001-12-20 | 2005-02-16 | Eli Lilly And Company | Inzulínová sloučenina s protrahovaným účinkem |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| AU2003239478A1 (en) | 2002-06-04 | 2003-12-22 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| FR2842209B1 (fr) | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| JP2006501820A (ja) | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| US7557183B2 (en) | 2003-03-19 | 2009-07-07 | Eli Lilly And Company | Polyethylene glycol linked GLP-1 compounds |
| ES2512499T3 (es) | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| CA2527743A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US20050124550A1 (en) | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| EP1704165B1 (en) | 2003-12-18 | 2010-03-17 | Novo Nordisk A/S | Glp-1 compounds |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| SG158158A1 (en) | 2004-12-22 | 2010-01-29 | Centocor Inc | Glp-1 agonists, compositions, methods and uses |
| EP1853627A2 (en) | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| CN101166545B (zh) | 2005-05-13 | 2011-06-15 | 伊莱利利公司 | Glp-1聚乙二醇化的化合物 |
| WO2006134340A2 (en) | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| BRPI0615573A2 (pt) | 2005-09-08 | 2011-05-24 | Tufts College | análogos de glp-1 estabilizados |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| EP1991574B1 (en) | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
| JP5312054B2 (ja) | 2006-03-15 | 2013-10-09 | ノボ・ノルデイスク・エー／エス | アミリンとインスリンの混合物 |
| JP5412273B2 (ja) * | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
| CA2648936C (en) | 2006-04-20 | 2013-07-09 | Amgen Inc. | Glp-1 compounds |
| EP2057189B1 (en) | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| JP5840345B2 (ja) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用 |
| EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| CN101842386A (zh) | 2007-09-05 | 2010-09-22 | 诺沃-诺迪斯克有限公司 | 截短的glp-1衍生物和它们的治疗用途 |
| GB0717399D0 (en) * | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| US20100256056A1 (en) | 2007-09-07 | 2010-10-07 | Zheng Xin Dong | Analogues of exendin-4 and exendin-3 |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| CN101854948A (zh) | 2007-09-11 | 2010-10-06 | 诺沃-诺迪斯克有限公司 | 含有胰岛淀粉样多肽类和长效胰岛素的合剂 |
| MX2010004297A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Antagonistas de glucagon. |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| RS58948B1 (sr) * | 2008-02-01 | 2019-08-30 | Ascendis Pharma As | Prolek koji sadrži linker koji se može sam odcepiti |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| MX2011006527A (es) | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Agentes medicinales unidos a dipeptido. |
| RU2550696C2 (ru) * | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| IN2012DN06437A (cg-RX-API-DMAC7.html) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2011
- 2011-06-14 RU RU2013103093/04A patent/RU2580317C2/ru not_active IP Right Cessation
- 2011-06-14 CN CN201180031415XA patent/CN103179979A/zh active Pending
- 2011-06-14 JP JP2013516609A patent/JP2013540102A/ja active Pending
- 2011-06-14 CA CA2796894A patent/CA2796894A1/en not_active Abandoned
- 2011-06-14 US US13/697,021 patent/US8778872B2/en active Active
- 2011-06-14 KR KR1020127033177A patent/KR20130102470A/ko not_active Withdrawn
- 2011-06-14 MX MX2012014576A patent/MX2012014576A/es not_active Application Discontinuation
- 2011-06-14 WO PCT/US2011/040330 patent/WO2011163012A2/en not_active Ceased
- 2011-06-14 EP EP11798640.6A patent/EP2588126A4/en not_active Withdrawn
- 2011-06-23 TW TW100121933A patent/TW201209062A/zh unknown
- 2011-06-23 AR ARP110102184A patent/AR081471A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130102470A (ko) | 2013-09-17 |
| MX2012014576A (es) | 2013-02-21 |
| CA2796894A1 (en) | 2011-12-29 |
| RU2013103093A (ru) | 2014-07-27 |
| TW201209062A (en) | 2012-03-01 |
| CN103179979A (zh) | 2013-06-26 |
| EP2588126A2 (en) | 2013-05-08 |
| WO2011163012A2 (en) | 2011-12-29 |
| WO2011163012A3 (en) | 2013-07-11 |
| US8778872B2 (en) | 2014-07-15 |
| US20130123462A1 (en) | 2013-05-16 |
| JP2013540102A (ja) | 2013-10-31 |
| RU2580317C2 (ru) | 2016-04-10 |
| EP2588126A4 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081471A1 (es) | Profarmacos de peptido de la superfamilia de glucagon basado en amida | |
| AR081984A1 (es) | Agentes medicinales unidos a dipeptido | |
| AR074811A1 (es) | Profarmaco de peptido de la superfamilia de glucagon basados en amida | |
| AR083052A1 (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| PE20210396A1 (es) | Moduladores de la via de estres integrada | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR061206A1 (es) | Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| NZ627878A (en) | P2x4 receptor antagonist | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| PH12014500638A1 (en) | Pyrrolopyrimidine and purine derivatives | |
| AR068756A1 (es) | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c | |
| EA200800484A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| PE20131163A1 (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
| PE20150623A1 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| BRPI0919810A8 (pt) | Compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR085990A1 (es) | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| AR085333A1 (es) | Derivados de pirazol microbicidas | |
| BR112016027778A2 (pt) | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |